Table 1 Clinical characteristics of surviving and deceased COVID-19 patients following hospitalization

Age

47 (41–53.5)

58 (52.5–63.5)

40 (34–45)

Epigenetic age

 DNAmAge

52.4 (46.7–60.1)

57.7 (54.5–63)

43.5 (40.4–52.1)

 DNAmAgeHannum

38.2 (33.3–45.1)

44.7 (39.9–51.4)

25.6 (23.5–33.3)

 DNAmPhenoAge

40.6 (34.3–50.1)

50.6 (44–58.8)

27.6 (20.6–38.1)

 DNAmAgeSkinBloodClock

46.5 (40.7–56.2)

54.4 (50.3–61)

38.6 (35.1–46.2)

 DNAmGrimAge

55.5 (50.8–61.2)

63.8 (60.3–68.7)

46 (39.4–52.7)

 Gender (male)

63 (93%)

19 (100%)

21 (100%)

 BMI (kg/m²)

27.4 (25.3–31.4)

25.7 (24.4–29.9)

28.7 (26–30.1)

 Duration of MV (days)

7 (4–13.5)

20 (14.5–26.5)

-

 ICU LoS (days)

14 (9.7–26.2)

24 (15–30.5)

-

 Hospital LoS (days)

30 (22–46)

25 (17–35)

-

 ECMO

7 (10%)

4 (21%)

 Nosocomial infections

35 (51.5%)

15 (78.9%)

-

 Convalescent plasma therapy

21 (30.9%)

6 (31.6%)

-

Diabetes status

 Non diabetes

34 (50%)

12 (63.2%)

–

 Pre-diabetes

2 (3%)

1 (5.3%)

–

 Diabetes

32 (47%)

6 (31.6%)

–

 Hypertension

29 (42.9%)

9 (47.4%)

–

 Coronary artery disease

4 (5.9%)

1 (5.3%)

–

 Chronic kidney failure

5 (7.4%)

2 (10.5%)

–

 Chronic heart failure

1 (1.5%)

0

–